Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Short Interest Update

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 745,300 shares, a growth of 113.1% from the February 28th total of 349,800 shares. Currently, 7.5% of the shares of the stock are sold short. Based on an average daily volume of 7,170,000 shares, the short-interest ratio is presently 0.1 days.

Petros Pharmaceuticals Price Performance

NASDAQ PTPI traded down $0.02 during trading on Friday, reaching $0.09. 14,877,153 shares of the company traded hands, compared to its average volume of 9,002,184. Petros Pharmaceuticals has a 1-year low of $0.05 and a 1-year high of $1.52. The company has a market cap of $1.01 million, a price-to-earnings ratio of -0.02 and a beta of 2.04. The stock’s 50 day moving average price is $0.18 and its two-hundred day moving average price is $0.28. The company has a debt-to-equity ratio of 1.58, a quick ratio of 0.74 and a current ratio of 0.85.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).